442 related articles for article (PubMed ID: 22349822)
41. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
42. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
43. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
Huang J; Dibble CC; Matsuzaki M; Manning BD
Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
[TBL] [Abstract][Full Text] [Related]
44. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
[TBL] [Abstract][Full Text] [Related]
45. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
46. Growing knowledge of the mTOR signaling network.
Huang K; Fingar DC
Semin Cell Dev Biol; 2014 Dec; 36():79-90. PubMed ID: 25242279
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
[TBL] [Abstract][Full Text] [Related]
48. mTOR-dependent cell survival mechanisms.
Hung CM; Garcia-Haro L; Sparks CA; Guertin DA
Cold Spring Harb Perspect Biol; 2012 Dec; 4(12):. PubMed ID: 23124837
[TBL] [Abstract][Full Text] [Related]
49. Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells.
Tandon M; Chen Z; Pratap J
Breast Cancer Res; 2014 Jan; 16(1):R16. PubMed ID: 24479521
[TBL] [Abstract][Full Text] [Related]
50. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
51. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
[TBL] [Abstract][Full Text] [Related]
52. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
[TBL] [Abstract][Full Text] [Related]
53. Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells.
Rosario FJ; Kanai Y; Powell TL; Jansson T
J Physiol; 2013 Feb; 591(3):609-25. PubMed ID: 23165769
[TBL] [Abstract][Full Text] [Related]
54. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
55. TSC1 controls distribution of actin fibers through its effect on function of Rho family of small GTPases and regulates cell migration and polarity.
Ohsawa M; Kobayashi T; Okura H; Igarashi T; Mizuguchi M; Hino O
PLoS One; 2013; 8(1):e54503. PubMed ID: 23355874
[TBL] [Abstract][Full Text] [Related]
56. TIS21
Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
[TBL] [Abstract][Full Text] [Related]
57. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size.
Saci A; Cantley LC; Carpenter CL
Mol Cell; 2011 Apr; 42(1):50-61. PubMed ID: 21474067
[TBL] [Abstract][Full Text] [Related]
58. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
[TBL] [Abstract][Full Text] [Related]
59. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
[TBL] [Abstract][Full Text] [Related]
60. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
